File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pharmacological effects and potential therapeutic targets of DT-13

TitlePharmacological effects and potential therapeutic targets of DT-13
Authors
KeywordsAnti-metastasis
Cardio protective
Anti-cancer
Pharmacological effects
DT-13
Issue Date2018
Citation
Biomedicine and Pharmacotherapy, 2018, v. 97, p. 255-263 How to Cite?
Abstract© 2017 Elsevier Masson SAS DT-13 is an isolated compound from Dwarf lillytruf tuber and currently among active research drugs by National Natural Science foundation of China for its several potential effects. The drug has been reported for its multiple pharmacological actions however no thorough review studies are available on it. Our present study is highlighting the pros and cons of DT-13 focusing on its potential pharmacological actions, therapeutic utilization and further exploration for novel targets. The drug possesses very low toxicity profile, quick onset and long duration of action with slow elimination that combinely makes it favorable for the clinical studies. In vivo and in vitro studies show that the drug regulates multiple cellular functions for its several pharmacological effects including, anti-adhesive effects via regulation of tissue factor and transforming growth factor; anti-migratory effects through indirect regulation of NM-IIA in the tumor microenvironment, Tissue factor, down-regulation of CCR5-CCL5 axis and MMP-2/9 inhibition; anti-metastatic effects via regulation of MMPs and tissue factor; pro-apoptotic effects by modulation of endocytosis of EGF receptor; anti-angiogenic effects via regulation of HIF-1α,ERK, Akt signalling and autophagy inducing characteristics by regulating PI3K/Akt/mTOR signalling pathway. In addition to anti-tumor activities, DT-13 has significant anti-inflammatory, cardioprotective, hepatoprotective and immunomodulating effects. Pharmaceutical dosage form and targeted drug delivery system for DT-13 has not been established yet. Moreover, DT-13, has not been studied for its action on brain, colorectal, hepatic, pancreatic, prostate and blood cancers. Similarly the effects of drug on carbohydrate and glucose metabolism is another niche yet to be explored. In some traditional therapies, crude drug from the plant is used against diabetic and neurological disorders that are not reported in scientific literature, however due to profound effects of DT-13 on blood and cerebral ischemic disorders, it is reasonable to hypothesize that there could be an association of DT-13 that require further exploration.
Persistent Identifierhttp://hdl.handle.net/10722/293103
ISSN
2021 Impact Factor: 7.419
2020 SCImago Journal Rankings: 1.323
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKhan, Ghulam Jilany-
dc.contributor.authorRizwan, Mohsin-
dc.contributor.authorAbbas, Muhammad-
dc.contributor.authorNaveed, Muhammad-
dc.contributor.authorBoyang, Yu-
dc.contributor.authorNaeem, Muhammad Ahsan-
dc.contributor.authorKhan, Sara-
dc.contributor.authorYuan, Shengtao-
dc.contributor.authorBaig, Mirza Muhammad Faran Ashraf-
dc.contributor.authorSun, Li-
dc.date.accessioned2020-11-19T09:01:59Z-
dc.date.available2020-11-19T09:01:59Z-
dc.date.issued2018-
dc.identifier.citationBiomedicine and Pharmacotherapy, 2018, v. 97, p. 255-263-
dc.identifier.issn0753-3322-
dc.identifier.urihttp://hdl.handle.net/10722/293103-
dc.description.abstract© 2017 Elsevier Masson SAS DT-13 is an isolated compound from Dwarf lillytruf tuber and currently among active research drugs by National Natural Science foundation of China for its several potential effects. The drug has been reported for its multiple pharmacological actions however no thorough review studies are available on it. Our present study is highlighting the pros and cons of DT-13 focusing on its potential pharmacological actions, therapeutic utilization and further exploration for novel targets. The drug possesses very low toxicity profile, quick onset and long duration of action with slow elimination that combinely makes it favorable for the clinical studies. In vivo and in vitro studies show that the drug regulates multiple cellular functions for its several pharmacological effects including, anti-adhesive effects via regulation of tissue factor and transforming growth factor; anti-migratory effects through indirect regulation of NM-IIA in the tumor microenvironment, Tissue factor, down-regulation of CCR5-CCL5 axis and MMP-2/9 inhibition; anti-metastatic effects via regulation of MMPs and tissue factor; pro-apoptotic effects by modulation of endocytosis of EGF receptor; anti-angiogenic effects via regulation of HIF-1α,ERK, Akt signalling and autophagy inducing characteristics by regulating PI3K/Akt/mTOR signalling pathway. In addition to anti-tumor activities, DT-13 has significant anti-inflammatory, cardioprotective, hepatoprotective and immunomodulating effects. Pharmaceutical dosage form and targeted drug delivery system for DT-13 has not been established yet. Moreover, DT-13, has not been studied for its action on brain, colorectal, hepatic, pancreatic, prostate and blood cancers. Similarly the effects of drug on carbohydrate and glucose metabolism is another niche yet to be explored. In some traditional therapies, crude drug from the plant is used against diabetic and neurological disorders that are not reported in scientific literature, however due to profound effects of DT-13 on blood and cerebral ischemic disorders, it is reasonable to hypothesize that there could be an association of DT-13 that require further exploration.-
dc.languageeng-
dc.relation.ispartofBiomedicine and Pharmacotherapy-
dc.subjectAnti-metastasis-
dc.subjectCardio protective-
dc.subjectAnti-cancer-
dc.subjectPharmacological effects-
dc.subjectDT-13-
dc.titlePharmacological effects and potential therapeutic targets of DT-13-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.biopha.2017.10.101-
dc.identifier.pmid29107216-
dc.identifier.scopuseid_2-s2.0-85032270098-
dc.identifier.volume97-
dc.identifier.spage255-
dc.identifier.epage263-
dc.identifier.eissn1950-6007-
dc.identifier.isiWOS:000419041300034-
dc.identifier.issnl0753-3322-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats